Speculation has been brewing all year about the prospect of Germany's Merck KGaA turning to M&A to bolster its unproductive drug pipeline, and today the company confirmed it has struck a deal, agreeing to buy Sigma-Aldrich for $17 billion.
Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion.
PCI, a contract pharma packaging company, has snapped up clinical trial supply operation Biotec, expanding its footprint across all phases of drug development.
Now that Bayer has announced a planned spinoff of its plastics business, all eyes are on what it may do with the proceeds. And the way some analysts see it, that money could go toward a pickup of animal health company Zoetis.
Who's afraid of a tax-inversion crackdown? Not Illinois-based Horizon Pharma, which plans to move its corporate address to Ireland today.
Endo's got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it's swallowed a poison pill to make sure it gets just that.
In its latest product acquisition, Integra LifeSciences is buying instrumentation lines from Medtronic for $60 million in cash. These include about 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments. The surgical products company will also gain a manufacturing facility in St. Aubin le Monial, France.
Just a few days after Auxilium Pharmaceuticals put out the word that pressure on the sales side was forcing a restructuring and the elimination of about 200 jobs, Endo has come along with a proposal to buy out the company for about $2.2 billion worth of cash and stock.
After months of battling between Allergan and its pursuers, Valeant and Pershing Square Capital Management, the two sides have reached a truce--at least when it comes to an upcoming shareholder meeting.
Remember all those industrial and investment promises Pfizer made when it was trying to snag AstraZeneca earlier this year? The body that polices U.K. dealmaking is eyeing new rules that would give it more power to enforce such promises, should Pfizer--or another company--come calling in the future.